Steven Cohen Atara Biotherapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$36 Billion
Q2 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.41 - $2.31 $24,295 - $39,803	-17,231 Reduced 3.01%	555,000 $821,000
Q2 2023 Aug 14, 2023	BUY	$1.5 - $3.04 $817,459 - $1.66 Million	544,973 Added 1999.31%	572,231 $921,000
Q1 2023 May 15, 2023	BUY	$2.8 - $5.46 $76,322 - $148,828	27,258 New	27,258 $79,000
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $11 Million - $33.6 Million	-3,847,200 Reduced 99.23%	30,000 $113,000
Q2 2022 Aug 15, 2022	SELL	$4.69 - $9.84 $1.06 Million - $2.23 Million	-226,476 Reduced 5.52%	3,877,200 $30.2 Million
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $4.3 Million - $8.61 Million	-510,024 Reduced 11.05%	4,103,676 $38.1 Million
Q4 2021 Feb 14, 2022	BUY	$14.7 - $19.89 $33.7 Million - $45.7 Million	2,295,400 Added 99.01%	4,613,700 $72.7 Million
Q3 2021 Nov 15, 2021	BUY	$11.99 - $17.9 $18.9 Million - $28.3 Million	1,578,400 Added 213.33%	2,318,300 $41.5 Million
Q2 2021 Aug 16, 2021	BUY	$12.89 - $16.58 $2.61 Million - $3.36 Million	202,800 Added 37.76%	739,900 $11.5 Million
Q1 2021 May 17, 2021	SELL	$14.0 - $20.72 $8.24 Million - $12.2 Million	-588,700 Reduced 52.29%	537,100 $7.71 Million
Q4 2020 Feb 16, 2021	BUY	$12.67 - $26.23 $14.3 Million - $29.5 Million	1,125,800 New	1,125,800 $22.1 Million
Q3 2020 Nov 16, 2020	SELL	$11.92 - $15.87 $1.58 Million - $2.11 Million	-132,754 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $999,637 - $1.98 Million	132,754 New	132,754 $1.93 Million
Q1 2019 May 15, 2019	SELL	$28.4 - $41.74 $15.7 Million - $23.1 Million	-553,100 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$30.9 - $42.97 $17.1 Million - $23.8 Million	553,100 New	553,100 $19.2 Million

Others Institutions Holding ATRA

# of Institutions

Shares Held

3.07M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $762M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account